Comparative Pharmacology
Head-to-head clinical analysis: ISRADIPINE versus VERARING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISRADIPINE versus VERARING.
ISRADIPINE vs VERARING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Not available
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
No established standard dosing. Veraring is not a recognized pharmaceutical agent.
None Documented
None Documented
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Clinical Note
moderateIsradipine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid."
Clinical Note
moderateIsradipine + Furosemide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide."
Clinical Note
moderateIsradipine + Bumetanide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide."
Clinical Note
moderateIsradipine + Travoprost
Terminal elimination half-life: 4.5 hours (range 3.5-6.0 hours). Clinical context: Steady state achieved within 24 hours; no accumulation with normal renal function.
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Renal elimination of unchanged drug and metabolites: 70% (60% unchanged, 40% as glucuronide conjugate); biliary/fecal: 30% (primarily metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker
"Isradipine may increase the hypotensive activities of Travoprost."